Overview
Biopharmaceutical firm's Q4 revenue beat analyst expectations
Q4 EPS and net income missed analyst estimates
Company strengthened balance sheet with $75 mln direct offering in January
Outlook
Altimmune plans to initiate Phase 3 MASH trial for pemvidutide in 2026
Company expects topline data from RECLAIM Phase 2 AUD trial in Q3 2026
Altimmune strengthens financial position with $75 mln direct offering in January 2026
Result Drivers
BREAKTHROUGH DESIGNATION - Pemvidutide received FDA Breakthrough Therapy Designation for MASH based on positive 24-week data
FINANCIAL STRENGTHENING - Company increased cash reserves to $340 mln through direct offering and ATM facility
CLINICAL PROGRESS - Positive 48-week Phase 2b trial data in MASH with significant improvements in fibrosis and inflammation markers
Company press release: ID:nGNX6RC2wf
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $26,000 | $710 (7 Analysts) |
Q4 EPS | Miss | -$0.27 | -$0.24 (9 Analysts) |
Q4 Net Income | Miss | -$27.36 mln | -$23.31 mln (7 Analysts) |
Q4 Income from Operations | Miss | -$28.89 mln | -$24.58 mln (7 Analysts) |
Q4 Basic EPS | -$0.27 | ||
Q4 Operating Expenses | $28.92 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Altimmune Inc is $20.00, about 368.4% above its March 4 closing price of $4.27
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments